Latest News in the pharma Industry

Research & Development

VR315 US completes clinical study

VR315 US completes clinical study

11 Jan 2016

VR315 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.

Read more 
Epigenomics receives FDA notification about status of pending approval decision for Epi proColon

Epigenomics receives FDA notification about status of pending approval decision for Epi proColon

8 Jan 2016

Final approval of the company's application is subject to the resolution of minor outstanding topics, such as the use of appropriate language in the product labeling.

Read more 
Regeneron and Sanofi announce sarilumab BLA Accepted for review by FDA

Regeneron and Sanofi announce sarilumab BLA Accepted for review by FDA

8 Jan 2016

Sarilumab is an investigational, human monoclonal antibody intended for the treatment of patients with active, moderate-to-severe rheumatoid arthritis

Read more 
Genomics and Vertex collaborate to identify target therapeutic pathways

Genomics and Vertex collaborate to identify target therapeutic pathways

7 Jan 2016

Genomics’ proprietary statistical analysis tools and integrated multi-phenotype database to be used to support R&D at Vertex Pharmaceuticals.

Read more 
Merck and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing

Merck and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing

7 Jan 2016

Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing.

Read more 
Gilead terminates Phase II study of simtuzumab in patients with idiopathic pulmonary fibrosis

Gilead terminates Phase II study of simtuzumab in patients with idiopathic pulmonary fibrosis

6 Jan 2016

The study's Data Monitoring Committee recommended that the study be terminated early due to lack of efficacy.

Read more 
MannKind and Sanofi to terminate Afrezza license and collaboration agreement

MannKind and Sanofi to terminate Afrezza license and collaboration agreement

5 Jan 2016

MannKind is now reviewing its strategic options for Afrezza

Read more 
Merck, Pfizer and Syndax announce collaboration to evaluate combination of avelumab and entinostat in ovarian cancer

Merck, Pfizer and Syndax announce collaboration to evaluate combination of avelumab and entinostat in ovarian cancer

4 Jan 2016

The three companies will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer.

Read more 
Epizyme announces first patient dosed in global clinical program evaluating tazemetostat in genetically defined solid tumours

Epizyme announces first patient dosed in global clinical program evaluating tazemetostat in genetically defined solid tumours

31 Dec 2015

US study sites now enrolling adults in registration-supporting Phase II study.

Read more 
Cellectis files first clinical trial application for UCART19, for hematological malignancies

Cellectis files first clinical trial application for UCART19, for hematological malignancies

31 Dec 2015

UCART19 is an allogeneic gene edited CAR T-cell product.

Read more 
Teikoku Pharma USA, Inc. announces FDA approval of docetaxel injection

Teikoku Pharma USA, Inc. announces FDA approval of docetaxel injection

30 Dec 2015

First non-alcohol formulation approved in the US.

Read more 
Seattle Genetics and BMS announce initiation of Phase I/II clinical trial of Adcetris in combination with Opdivo in relapsed or refractory non-Hodgkin lymphoma

Seattle Genetics and BMS announce initiation of Phase I/II clinical trial of Adcetris in combination with Opdivo in relapsed or refractory non-Hodgkin lymphoma

30 Dec 2015

Second of two planned trials combining Adcetris and Opdivo under clinical collaboration agreement.

Read more